Moderna, a biotech firm, expanded its partnership with Benchling, the leading life science R&D platform, to increase drug development and aid scientific innovation and discovery. Benchling will optimize AI digital frameworks for scientists and researchers to streamline workflows, giving companies the jump start they need to access the medicine revolution powered by AI.
Set A New Metric For Digital Transformation In Biotechnology
Benchling‘s and Moderna’s partnership goals are tailored towards re-evaluating biotechnology, morphing it into a forward-thinking industry. Their collaborative efforts focus on consolidating vast amounts of research data frameworks that enable advanced analytical AI scrutiny.
The Vice President of Digital at Moderna, Wade Davis, explained how the company operates with the belief that ‘technology and science together drive breakthroughs in medicine.’ He further explained how Benchling’s collaboration with Moderna will enhance the AI backbone of their science experts when he said, ‘Our scientists have access to a strong foundation for AI, and our computational scientists and engineers are empowered to do truly cutting-edge work. Everything we are doing becomes possible because AI is creating extraordinary opportunities in science.
Bringing Together Modern Research with Evolving Technology
For Benchling to assist Moderna in eliminating their gaps, ultimately serving the business’s evolving needs, Moderna’s biotechnical research and technology development groups needed a sophisticated step-change digital system for their pharmaceutical development pipeline. As part of their new collaboration, Benchling is currently utilizing further modifications with its work to provide its clients with new and competitive agile options.
With the step change gap formerly identified by Moderna, the Benchling developer platform is currently aiding its users with deploying tailored, automated, editable experimental templates readily integrated with proprietary machine learning algorithms capable of executing tasks in real time, streamlining execution without compromising precision when executed seamlessly.
This strategic shift alleviates the often significant new research initiative configuration burdens, enabling the digital teams to focus on innovation rather than system upkeep silos maintenance.
By Benchling’s platform being instantiated throughout all of Moderna’s research arms, scientists will be able to design intricate experiments, track samples, and analyze complex results—all within a singular, seamless digital environment. This ‘one-stop shop’ approach not only streamlines data management but also mitigates risks of error associated with data handling through disjointed tools and platforms.
In addition, the collaboration helps solve a chronic problem that has plagued the industry: how to effectively manage integration of both structured (quantitative data) and unstructured (images, notes, and free text) data from multiple heterogeneous research operation silos. By providing this critical solution, Moderna and Benchling enable expansive access to AI analysis infrastructure across numerous therapeutic areas, which promises to transform current paradigms of discovering new insights and accelerating the development of treatments and cures.
It is evident from the work being done by Moderna and Benchling that they are not simply improving research workflows; they are transforming the very nature of conduct in modern biotech research. By setting benchmarks for the digital framework that supports AI-enabled R&D, they are enabling a future where the intersection of technology and biology is harnessed to expedite the availability of pivotal therapeutics to patients all over the globe.
